• 1
    Dufour MC. Chronic liver disease and cirrhosis. In: EverhartJE, ed. Digestive Diseases in the United States: Epidemiology and Impact. Washington, DC: US Government Printing Office, 1994: 61346.
  • 2
    Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 36: 22742.
  • 3
    Anonymous. The Burden of Gastrointestinal Diseases. Bethesda, MD: The American Gastroenterologica Association, 2001: 4160.
  • 4
    Kanwal F, Hays RD, Kilbourne AM, Dulai GS, Gralnek IM. Are physician-derived disease severity indices associated with health-related quality of life in patients with end-stage liver disease? Am J Gastroenterol 2004; 99: 172632.
    Direct Link:
  • 5
    Marchesini G, Bianchi G, Amodio P, et al. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology 2001; 120: 1708.
  • 6
    Steel JL, Chopra K, Olek MC, Carr BI. Health-related quality of life: hepatocellular carcinoma, chronic liver disease, and the general population. Qual Life Res 2007; 16: 20315.
  • 7
    Younossi ZM, McCormick M, Price LL, et al. Impact of liver transplantation on health-related quality of life. Liver Transpl 2000; 6: 77983.
  • 8
    Younossi ZM, Kiwi ML, Boparai N, Price LL, Guyatt G. Cholestatic liver diseases and health-related quality of life. Am J Gastroenterol 2000; 95: 497502.
    Direct Link:
  • 9
    Younossi ZM, Boparai N, Price LL, Kiwi ML, McCormick M, Guyatt G. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol 2001; 96: 2199205.
    Direct Link:
  • 10
    Younossi ZM. Chronic liver disease and health-related quality of life. Gastroenterology 2001; 120: 3057.
  • 11
    Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993; 118: 6229.
  • 12
    Devinsky O, Vickrey BG, Cramer J, et al. Development of the quality of life in epilepsy inventory. Epilepsia 1995; 36: 1089104.
  • 13
    Hofer S, Lim L, Guyatt G, Oldridge N. The MacNew Heart Disease health-related quality of life instrument: a summary. Health Qual Life Outcomes 2004; 2: 3.
  • 14
    Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 1998; 36: 100212.
  • 15
    Puhan MA, Behnke M, Frey M, et al. Self-administration and interviewer-administration of the German Chronic Respiratory Questionnaire: instrument development and assessment of validity and reliability in two randomised studies. Health Qual Life Outcomes 2004; 2: 1.
  • 16
    Wu AW, Huang IC, Gifford AL, Spritzer KL, Bozzette SA, Hays RD. Creating a crosswalk to estimate AIDS Clinical Trials Group quality of life scores in a nationally representative sample of persons in care for HIV in the United States. HIV Clin Trials 2005; 6: 14757.
  • 17
    Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987; 40: 1718.
  • 18
    Kirshner B, Guyatt G. A methodological framework for assessing health indices. J Chronic Dis 1985; 38: 2736.
  • 19
    Atherly A. Condition-specific measures. In: KaneR, ed. Understanding Health Care Outcomes Research. Sadbury, MA, USA: Jones and Bartlet Publishers 2004: 165184.
  • 20
    Kessler RC, Mroczek DK. Measuring the effects of medical interventions. Med Care 1995; 4(Suppl.): AS10919.
  • 21
    Saab S, Ibrahim AB, Shpaner A, et al. MELD fails to measure quality of life in liver transplant candidates. Liver Transpl 2005; 11: 21823.
  • 22
    Gralnek IM, Hays RD, Kilbourne A, et al. Development and evaluation of the Liver Disease Quality of Life instrument in persons with advanced, chronic liver disease – the LDQOL 1.0. Am J Gastroenterol 2000; 95: 355265.
  • 23
    Ware JE, Snow KK, Kosinski MK, Gadnek B. Scoring the SF-36. In: WareJE, ed. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: Nimrod Press, 1992: 6.
  • 24
    Tubbs JD. Maximum R2 Improvement (MAXR). Available at: Accessed on 15 June 2008.
  • 25
    Hays RD, Anderson RT, Revicki D. Assessing reliability and validity of measurement in clinical trials. In: StaquetMJ, HaysRD, FayersPM, eds. Quality of Life Assessment in Clinical Trials: Methods and Practice. Oxford: Oxford University Press, 1998: 16982.
  • 26
    Litwin MS. Scaling and scoring. In: LitwinMS, ed. How to Measure Survey Reliability and Validity. Thousand Oaks, CA, USA: SAGE Publications Inc., 1995: 4752.
  • 27
    Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 46470.
  • 28
    Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 916.
  • 29
    Campbell DT, Fiske DW. Convergent and discriminant validation by the multitrait-multimethod matrix. Psychol Bull 1959; 56: 81105.
  • 30
    Ware JE Jr, Gandek B. Methods for testing data quality, scaling assumptions, and reliability: the IQOLA Project approach. International Quality of Life Assessment. J Clin Epidemiol 1998; 51: 94552.
  • 31
    Guyatt GH, Deyo RA, Charlson M, Levine MN, Mitchell A. Responsiveness and validity in health status measurement: a clarification. J Clin Epidemiol 1989; 42: 4038.
  • 32
    Belle SH, Porayko MK, Hoofnagle JH, Lake JR, Zetterman RK. Changes in quality of life after liver transplantation among adults. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Liver Transplantation Database (LTD). Liver Transpl Surg 1997; 3: 93104.
  • 33
    Gross CR, Malinchoc M, Kim WR, Evans RW, Wiesner RH, Petz JL, et al. Quality of life before and after liver transplantation for cholestatic liver disease. Hepatology 1999; 29: 35664.
  • 34
    Cohen J. Statistical Power Analysis for the Behavioral Sciences. London: Academic Press, 1969.
  • 35
    Hays RD, Woolley JM. The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it?. Pharmacoeconomics 2000; 18: 41923.
  • 36
    Tome S, Wells JT, Said A, Lucey MR. Quality of life after liver transplantation. A systematic review. J Hepatol 2008; 48: 56777.
  • 37
    Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999; 45: 295300.
  • 38
    Mas A, Rodes J, Sunyer L, et al. Comparison of rifaxamin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled trial. J Hepatol 2003; 38: 518.
  • 39
    Salerno F, Cammà C, Enea M, et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007; 133: 82534.
  • 40
    Di MarcoV, Almasio PL, Ferraro D, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007; 47: 48491.
  • 41
    Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41: 790800.
  • 42
    Steel JL, Eton DT, Cella D, Olek MC, Carr BI. Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann Oncol 2006; 17: 30412.
  • 43
    Sorrell JH, Brown JR. Sexual functioning in patients with end-stage liver disease before and after transplantation. Liver Transpl 2006; 12: 14737.